# Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

> **NCT02638805** · PHASE3 · COMPLETED · sponsor: **Intarcia Therapeutics** · enrollment: 136 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** ITCA 650 Osmotic Mini Pump 20/60 mcg/day
- **DRUG:** ITCA 650 Osmotic Mini Pump 60 mcg/day
- **DRUG:** Metformin
- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT02638805
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02638805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02638805, "Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02638805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*